JP7386537B2 - ワクチンt細胞エンハンサー - Google Patents

ワクチンt細胞エンハンサー Download PDF

Info

Publication number
JP7386537B2
JP7386537B2 JP2020524616A JP2020524616A JP7386537B2 JP 7386537 B2 JP7386537 B2 JP 7386537B2 JP 2020524616 A JP2020524616 A JP 2020524616A JP 2020524616 A JP2020524616 A JP 2020524616A JP 7386537 B2 JP7386537 B2 JP 7386537B2
Authority
JP
Japan
Prior art keywords
antigens
vector
polypeptide
inv
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020524616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502076A (ja
Inventor
ニコシア,アルフレード
スカルセッリ,エリーザ
フォルゴリ,アントネッラ
ラーム,アルミン
Original Assignee
ノイスコム アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノイスコム アーゲー filed Critical ノイスコム アーゲー
Publication of JP2021502076A publication Critical patent/JP2021502076A/ja
Priority to JP2023063975A priority Critical patent/JP7485422B2/ja
Application granted granted Critical
Publication of JP7386537B2 publication Critical patent/JP7386537B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2020524616A 2017-11-03 2018-11-02 ワクチンt細胞エンハンサー Active JP7386537B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023063975A JP7485422B2 (ja) 2017-11-03 2023-04-11 ワクチンt細胞エンハンサー

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17200036.6 2017-11-03
EP17200036 2017-11-03
EP17211235.1 2017-12-29
EP17211235 2017-12-29
PCT/EP2018/080027 WO2019086615A1 (en) 2017-11-03 2018-11-02 Vaccine t cell enhancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023063975A Division JP7485422B2 (ja) 2017-11-03 2023-04-11 ワクチンt細胞エンハンサー

Publications (2)

Publication Number Publication Date
JP2021502076A JP2021502076A (ja) 2021-01-28
JP7386537B2 true JP7386537B2 (ja) 2023-11-27

Family

ID=64332267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020524616A Active JP7386537B2 (ja) 2017-11-03 2018-11-02 ワクチンt細胞エンハンサー
JP2023063975A Active JP7485422B2 (ja) 2017-11-03 2023-04-11 ワクチンt細胞エンハンサー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023063975A Active JP7485422B2 (ja) 2017-11-03 2023-04-11 ワクチンt細胞エンハンサー

Country Status (12)

Country Link
US (1) US11912743B2 (cg-RX-API-DMAC7.html)
EP (1) EP3703744A1 (cg-RX-API-DMAC7.html)
JP (2) JP7386537B2 (cg-RX-API-DMAC7.html)
KR (1) KR102747530B1 (cg-RX-API-DMAC7.html)
CN (1) CN111670046B (cg-RX-API-DMAC7.html)
AU (1) AU2018358019B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020008308A2 (cg-RX-API-DMAC7.html)
CA (1) CA3078692A1 (cg-RX-API-DMAC7.html)
IL (1) IL274409B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004552A (cg-RX-API-DMAC7.html)
SG (1) SG11202003799RA (cg-RX-API-DMAC7.html)
WO (1) WO2019086615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12576143B2 (en) * 2018-10-19 2026-03-17 Nouscom Ag Teleost invariant chain cancer vaccine
CN113424264B (zh) * 2018-11-15 2024-04-12 Nouscom股份公司 用于生成个性化癌症疫苗的癌症突变选择
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2021209897A1 (en) * 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
AU2022414274A1 (en) * 2021-12-16 2024-08-01 Janssen Biotech, Inc. Prostate cancer vaccines and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160304582A1 (en) 2013-12-04 2016-10-20 Isis Innovation Limited Molecular adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4814800B2 (ja) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
SI2865387T1 (sl) * 2008-11-21 2019-10-30 Kobenhavns Univ University Of Copenhagen Primiranje imunskega odziva
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP3190415B1 (en) * 2014-07-25 2019-05-01 Riken Memory invariant nkt cell marker
US20200230220A1 (en) * 2017-07-12 2020-07-23 Nouscom Ag Neoantigen vaccine composition for treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160304582A1 (en) 2013-12-04 2016-10-20 Isis Innovation Limited Molecular adjuvant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A0A0E3JX56_SINCH[online],2015年06月24日,https://www.uniprot.org/uniprot/A0A0E3JX56.txt?version=1参照
Molecular Therapy,2014年05月,Vol.22, No.5,pp.1039-1047,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015230/参照
PLOS ONE,2014年06月,Vol.9, Issue6,e100538,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0100538参照

Also Published As

Publication number Publication date
KR20200076696A (ko) 2020-06-29
RU2020115109A (ru) 2021-12-03
CN111670046B (zh) 2024-11-08
JP7485422B2 (ja) 2024-05-16
RU2020115109A3 (cg-RX-API-DMAC7.html) 2021-12-03
AU2018358019B2 (en) 2023-05-11
BR112020008308A2 (pt) 2020-11-17
IL274409B1 (en) 2023-07-01
SG11202003799RA (en) 2020-05-28
US20210363201A1 (en) 2021-11-25
US11912743B2 (en) 2024-02-27
JP2023089103A (ja) 2023-06-27
JP2021502076A (ja) 2021-01-28
CN111670046A (zh) 2020-09-15
AU2018358019A1 (en) 2020-04-23
NZ763337A (en) 2025-02-28
KR102747530B1 (ko) 2024-12-27
CA3078692A1 (en) 2019-05-09
IL274409B2 (en) 2023-11-01
EP3703744A1 (en) 2020-09-09
IL274409A (en) 2020-06-30
MX2020004552A (es) 2020-10-07
WO2019086615A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
JP7485422B2 (ja) ワクチンt細胞エンハンサー
JP7638526B2 (ja) 硬骨魚類インバリアント鎖癌ワクチン
AU2018300051B2 (en) Neoantigen vaccine composition for treatment of cancer
EP4175664A2 (en) Prostate neoantigens and their uses
RU2794196C2 (ru) Усилитель t-клеточного ответа на вакцину
RU2808567C2 (ru) Противораковая вакцина с инвариантной цепью из костистых рыб
CA3109541C (en) Teleost invariant chain cancer vaccine
RU2782261C2 (ru) Вакцинная композиция для лечения рака
NZ759944B2 (en) Neoantigen vaccine composition for treatment of cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230411

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230419

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230420

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231107

R150 Certificate of patent or registration of utility model

Ref document number: 7386537

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150